Jaguar Health Reports the US FDA’s Renewal of Conditional Approval for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs
Shots:
- The US FDA has renewed the conditional approval (in effect until Dec 21, 2025) of Canalevia-CA1 for the treatment of dogs with chemotherapy-induced diarrhea
- Canalevia-CA1 received the FDA’s conditional approval in Dec 2021, based on a study of 24 dogs, 75% (treated group) vs 25% (control group) of dogs showed diarrhea resolution by day 3 and 33% of treated dogs improved within 48hrs., compared to none in the control group
- Canalevia-CA1 is a delayed-release tablet formulated using crofelemer, derived from the Croton lechleri tree, for canine health
Ref: Jaguar Health | Image: Jaguar Health
Related News:- The US FDA Approves Jaguar Health’s Clinical Trial Protocol for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
